Why Does AndroGel Absorption Vary? The Biology of Inconsistent Testosterone Delivery

The Stratum Corneum: Your Skin's Rate-Limiting Barrier

The stratum corneum is the single greatest determinant of how much testosterone actually enters your bloodstream from a topical gel. This dead-cell layer, only 10, 20 micrometers thick, functions as a lipid-rich brick-and-mortar barrier where corneocytes (the "bricks") sit embedded in lamellar lipid bilayers (the "mortar") composed of ceramides, cholesterol, and free fatty acids 1.

Testosterone, a lipophilic steroid with a molecular weight of 288.4 Da and a log P of approximately 3.3, permeates primarily through the intercellular lipid pathway. The rate of permeation follows Fick's first law of diffusion: flux equals the partition coefficient multiplied by the diffusion coefficient, divided by membrane thickness. Any change to these variables directly alters how much drug crosses per unit time.

What makes absorption variable rather than merely low is that stratum corneum properties differ across anatomical sites by as much as 3-fold. A study published in the British Journal of Dermatology measured transepidermal water loss (a proxy for barrier function) and found forearm permeability was 2.8 times lower than scrotal skin and 1.6 times lower than shoulder skin 2. The FDA-approved application sites for AndroGel (shoulders, upper arms, abdomen) were selected for their intermediate permeability, but even within these approved sites, person-to-person differences in corneocyte layers and lipid composition produce a coefficient of variation exceeding 30% 3.

Why 86 to 91% of the Applied Dose Never Reaches Your Blood

The low overall bioavailability of transdermal testosterone is not a flaw in formulation design. It is a consequence of the skin's primary biological function as a barrier organ. The original pharmacokinetic study for AndroGel 1% (Swerdloff et al., 2000) demonstrated that only about 10% of the applied testosterone dose appeared in 24-hour urine collections, confirming systemic bioavailability of approximately 9 to 14% 4.

Where does the rest go? Three fates account for the missing drug. First, a reservoir forms within the stratum corneum itself, where testosterone partitions into the intercellular lipids but never diffuses deeply enough to reach dermal capillaries before the next shower or clothing contact removes it. Second, cutaneous metabolism by 5-alpha reductase and 17-beta hydroxysteroid dehydrogenase converts a portion of testosterone to dihydrotestosterone and androstenedione locally within the skin, before it reaches systemic circulation 5. Third, mechanical loss through transfer to clothing, bedding, or other people removes drug from the application surface entirely.

The hydroalcoholic vehicle in AndroGel (ethanol and isopropyl myristate) enhances initial penetration by temporarily disrupting lipid packing in the stratum corneum. But ethanol evaporates within 2 to 5 minutes of application. Once the vehicle evaporates, the rate-enhancing effect disappears and remaining testosterone on the skin surface depends entirely on passive diffusion through an intact barrier.

Intra-Individual Variability: The 20 to 40% Daily Swing

Even when the same patient applies the same dose to the same site at the same time each day, serum testosterone concentrations fluctuate substantially. The key bioequivalence study for AndroGel 1.62% reported intra-subject coefficients of variation (CV) of 27 to 35% for Cmax and 22 to 28% for AUC0, 24 6.

These swings have real clinical consequences. A man targeting a mid-range trough of 500 ng/dL might see values anywhere from 350 to 700 ng/dL on sequential lab draws without changing anything about his regimen. This creates diagnostic confusion, unnecessary dose adjustments, and patient frustration.

The biological drivers of day-to-day variability include skin hydration status (which can shift stratum corneum diffusivity by 2, 3 fold), ambient temperature and humidity (higher temperature increases diffusion coefficients), physical activity timing relative to application (sweating within 1 to 2 hours can wash gel from the surface), and circadian variation in cutaneous blood flow (dermal perfusion peaks in the afternoon, potentially altering sink conditions for drug already in the dermis) 7.

Application Site Matters More Than Most Patients Realize

The Endocrine Society's 2018 Clinical Practice Guideline for testosterone therapy notes that application site selection is a primary determinant of serum testosterone levels achieved with topical formulations 8. This is not merely a recommendation of convenience.

Comparative pharmacokinetic data show clear site-dependent differences. Scrotal application of testosterone gel produces approximately 5, 8 times higher DHT levels due to concentrated 5-alpha reductase activity in genital skin 9. Shoulder and upper arm skin offer moderate permeability with less first-pass cutaneous metabolism. Abdominal skin has higher subcutaneous fat content that can act as an additional depot, potentially smoothing Cmax but reducing overall bioavailability in obese patients.

A crossover pharmacokinetic study in 12 hypogonadal men showed that switching from upper arm to abdominal application reduced mean Cmax by 18% and shifted Tmax from 4 hours to 6 hours post-dose 10. Patients who rotate sites daily, even among FDA-approved locations, introduce an additional source of variability.

The practical implication is straightforward: pick one site and stay consistent. The 2018 Endocrine Society guideline recommends measuring serum testosterone 2 to 8 hours after application (depending on formulation) and adjusting dose based on levels from a consistent application routine 8.

The Role of Skin Thickness, Hair Density, and Body Composition

Not all skin is created equal, and individual anatomy compounds the population-level variability. Epidermal thickness ranges from 0.05 mm on the eyelids to 1.5 mm on the palms. At FDA-approved application sites, thickness varies between 0.06 mm and 0.15 mm, introducing a 2.5-fold range in diffusion path length alone 11.

Hair follicles represent an alternative penetration pathway. The follicular route bypasses the stratum corneum entirely, allowing drug to reach the dermis through the hair canal. In areas with higher follicular density (like the upper chest in men), this shunt pathway can contribute 10 to 40% of total permeation during the first hour after application 12. After 2 to 3 hours, the intercellular route dominates regardless of follicular density.

Body composition plays an indirect but significant role. Obese patients (BMI >30) show lower serum testosterone responses to identical topical doses. The TIMES-2 study found that men with BMI >35 required approximately 30% higher doses to achieve equivalent serum concentrations compared to men with BMI 25, 30, partially due to increased subcutaneous adipose tissue sequestering lipophilic testosterone before it reaches dermal capillaries 13.

Dr. Adrian Dobs, an endocrinologist at Johns Hopkins who led early transdermal testosterone pharmacokinetic studies, has stated: "The skin is not a passive membrane. It is a metabolically active organ that processes testosterone before systemic delivery, and this processing varies enormously between patients."

Hydroalcoholic Vehicle Dynamics: What Happens in the First Five Minutes

The ethanol in AndroGel serves two purposes: it temporarily fluidizes stratum corneum lipids (creating transient channels for enhanced diffusion) and it acts as a volatile solvent that deposits a thin film of testosterone on the skin surface as it evaporates. The rate of ethanol evaporation depends on ambient humidity, air movement, and skin temperature 14.

In dry, warm conditions (low humidity, skin temperature above 34°C), ethanol evaporates within 90 seconds. The window of enhanced permeation is correspondingly brief. In cool, humid environments, evaporation takes 3 to 5 minutes, potentially allowing more drug to penetrate during the high-flux phase. This means the same patient applying the same dose can achieve meaningfully different peak concentrations depending on whether the bathroom was steamy from a shower or cool and dry.

The FDA prescribing information for AndroGel 1.62% specifically instructs patients to allow the gel to dry completely before dressing, and to avoid showering or swimming for at least 2 hours (5 hours for the 1% formulation) 15. These instructions exist precisely because premature covering or washing during the critical absorption window significantly reduces bioavailability.

Sweating, Showering, and the Two-Hour Rule

Physical activity that produces sweating within 2 hours of gel application can reduce testosterone absorption by 30 to 50%. A pharmacokinetic substudy within the AndroGel registration program assessed the effect of showering at various intervals post-application. Showering at 1 hour reduced AUC0, 24 by approximately 35% compared to no shower. Showering at 2 hours reduced it by 13%. By 6 hours, showering had no measurable effect on total systemic exposure 15.

Sweating creates a different mechanism of drug loss compared to showering. Eccrine sweat carries dissolved drug from the skin surface and stratum corneum reservoir onto the skin surface where it spreads, evaporates, or transfers to clothing. The eccrine glands on the shoulders produce approximately 0.5 to 1.0 mg sweat per cm² per hour during moderate exercise 16. This volume is sufficient to solubilize and remove a substantial fraction of the testosterone reservoir that has not yet diffused past the viable epidermis.

Strategies to Reduce Absorption Variability

Managing variable absorption requires addressing the modifiable biological and behavioral factors systematically.

Consistent site selection. Apply to the same anatomical location daily. The shoulders and upper arms offer a good balance of surface area, moderate permeability, and ease of coverage with clothing to prevent transfer 8.

Timing relative to bathing. Apply after complete skin drying, at least 10 minutes post-shower. Showering before application transiently increases stratum corneum hydration, which can increase initial flux but also increases variability because hydration dissipates unpredictably.

Ambient conditions. Apply in a room-temperature environment. Avoid applying in a steamy bathroom immediately after a hot shower, as the elevated humidity alters ethanol evaporation kinetics.

Activity restriction. Avoid exercise or activities that produce sweating for a minimum of 2 hours post-application (5 hours is preferable for the 1% formulation).

Skin preparation. Do not apply to broken, irritated, or recently shaved skin. Do not use other topical products (sunscreen, moisturizer, corticosteroids) on the application site within 2 hours, as these can alter stratum corneum lipid packing and partition coefficients.

Monitoring protocol. When checking serum levels, apply gel at the same time relative to the blood draw on each occasion. The Endocrine Society recommends measuring levels 2 to 8 hours post-application for peak assessment, and clinicians should ensure the timing is identical across visits for meaningful dose titration 8.

When Variable Absorption Warrants a Formulation Switch

Some patients will never achieve stable levels on topical testosterone regardless of optimization. The American Urological Association's 2018 guideline on testosterone deficiency acknowledges that patients with "poor or erratic" absorption on topical formulations may benefit from switching to injectable testosterone (cypionate or enanthate) or subcutaneous pellets, which bypass the skin barrier entirely 17.

Dr. Abraham Morgentaler of Harvard Medical School has noted: "If a patient has followed all application instructions correctly for 4 to 6 weeks and serum testosterone remains below the target range or fluctuates by more than 50% between draws, the issue is likely intrinsic skin biology rather than compliance, and a different delivery route should be considered."

Clinical indicators that suggest intrinsic poor absorption include: serum testosterone consistently below 400 ng/dL despite maximum gel dose (81 mg/day of 1.62% formulation), coefficient of variation exceeding 50% on three or more draws with identical timing, and persistent hypogonadal symptoms despite "adequate" mean serum levels (suggesting the troughs are clinically significant even if peaks are acceptable).

Injectable testosterone cypionate at 100 to 200 mg every 1 to 2 weeks produces steady-state trough levels with a CV of approximately 15 to 20%, significantly less variable than topical delivery 18. Subcutaneous testosterone pellets (Testopel) produce even more stable levels over 3 to 6 months but require an in-office insertion procedure.

The FAERS Signal: How Common Is Clinically Meaningful Variability?

FDA Adverse Event Reporting System (FAERS) data for testosterone topical products show that "drug ineffective" and "drug effect decreased" represent approximately 8 to 12% of all reported adverse events for AndroGel, a higher proportion than for injectable formulations 19. While FAERS reports cannot establish causality or incidence rates, this pattern is consistent with a population of patients experiencing clinically meaningful absorption variability.

The phase 3 registration trials for AndroGel 1% showed that approximately 15% of patients failed to achieve target serum testosterone (300 to 1000 ng/dL) at the starting dose and required upward titration 4. Among those titrated to maximum dose, approximately 5 to 8% still did not reach target levels, representing the subset with intrinsically poor percutaneous absorption.

Post-marketing surveillance data collected by AbbVie and reviewed by the FDA during the 2014 testosterone risk evaluation confirmed that dose adjustments are more frequent with topical than injectable formulations, with approximately 40% of topical patients requiring at least one dose change in the first year compared to 20% of injectable patients 20.